Open questions on basal insulin therapy in T2D: a Delphi consensus

• Published in: Acta diabetologica
• Main Authors: Buzzetti, Raffaella, Candido, Riccardo, Esposito, Katherine, Giaccari, Andrea, Mannucci, Edoardo, Nicolucci, Antonio, Russo, Giuseppina T
• Format: Journal Article
• Language: English
• Published: Germany 20.05.2024
• Subjects: Therapeutic inertia; Type 2 diabetes; Basal insulin therapy; Expert consensus
• ISSN: 1432-5233; 1432-5233
• DOI: 10.1007/s00592-024-02285-2

The revolution in the therapeutic approach to type 2 diabetes (T2D) requires a rethinking of the positioning of basal insulin (BI) therapy. Given the considerable number of open questions, a group of experts was convened with the aim of providing, through a Delphi consensus method, practical guidance for doctors. A group of 6 experts developed a series of 29 statements on: the role of metabolic control in light of the most recent guidelines; BI intensification strategies: (1) add-on versus switch; (2) inertia in starting and titrating; (3) free versus fixed ratio combination; basal-bolus intensification and de-intensification strategies; second generation analogues of BI (2BI). A panel of 31 diabetologists, by accessing a dedicated website, assigned each statement a relevance score on a 9-point scale. The RAND/UCLA Appropriateness Method was adopted to assess the existence of disagreement among participants. Panelists showed agreement for all 29 statements, of which 26 were considered relevant, one was considered not relevant and two were of uncertain relevance. Panelists agreed that the availability of new classes of drugs often allows the postponement of BI and the simplification of therapy. It remains essential to promptly initiate and titrate BI when required. BI should always, unless contraindicated, be started in addition to, and not as a replacement, for ongoing treatments with cardiorenal benefits. 2BIs should be preferred for their pharmacological profile, greater ease of self-titration and flexibility of administration. In a continuously evolving scenario, BI therapy still represents an important option in the management of T2D patients.